Zobrazeno 1 - 10
of 31
pro vyhledávání: '"Megumi Furuta"'
Autor:
Yuta Takashima, Naofumi Shinagawa, Daisuke Morinaga, Junichi Nakamura, Megumi Furuta, Tetsuaki Shoji, Hajime Asahina, Eiki Kikuchi, Junko Kikuchi, Jun Sakakibara-Konishi, Ichizo Tsujino, Satoshi Konno
Publikováno v:
BMC Pulmonary Medicine, Vol 22, Iss 1, Pp 1-8 (2022)
Abstract Background Endobronchial ultrasound (EBUS)-guided transbronchial biopsy (TBB) facilitates the diagnosis of various respiratory diseases. The safety of performing EBUS-guided TBB in patients with a finding of pulmonary hypertension (PH) is co
Externí odkaz:
https://doaj.org/article/09629def4f4349cb9bd541568247e953
Publikováno v:
Case Reports in Oncology, Vol 14, Iss 3, Pp 1418-1421 (2021)
Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most serious adverse effects of chemotherapy. We experienced carboplatin (CBDCA)-induced akathisia-like CIPN, which was significantly attenuated by pregabalin administration, and report
Externí odkaz:
https://doaj.org/article/d607cbd4ffef49cea0f449cdf068b3ef
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Kazutaka Fujita, Ryo Arai, Satoshi Shoji, Ryota Saito, Motoko Nomura, Takamasa Hotta, Hajime Asahina, Masanori Kawakami, Ichiro Nakachi, Yukihiro Hasegawa, Kohei Okafuji, Aya Suzuki, Akihiko Miyanaga, Noriaki Sunaga, Hiromi Nagashima, Naoya Ikeda, Satoshi Watanabe, Yoshiaki Nagai, Megumi Furuta, Hidenori Kage, Daisuke Arai, Tatsuro Fukuhara, Masayuki Nakayama, Satoshi Morita, Kunihiko Kobayashi, Koichi Hagiwara
Publikováno v:
Cancer Science.
Autor:
Daisuke Morinaga, Jun Sakakibara, Megumi Furuta, Naofumi Shinagawa, Tomohiro Goda, Kento Wakabayashi, Emi Takakuwa, Taichi Takashina, Satoshi Konno
Publikováno v:
Haigan. 62:107-114
Autor:
Yasuyuki Ikezawa, Hidenori Mizugaki, Ryo Morita, Kazunari Tateishi, Keiki Yokoo, Toshiyuki Sumi, Hajime Kikuchi, Yasuo Kitamura, Atsushi Nakamura, Maki Kobayashi, Mari Aso, Nozomu Kimura, Fumiaki Yoshiike, Megumi Furuta, Hisashi Tanaka, Motoki Sekikawa, Tsutomu Hachiya, Keiichi Nakamura, Mototsugu Shimokawa, Satoshi Oizumi
Publikováno v:
Cancer Science. 113:2109-2117
It is not clear whether pembrolizumab monotherapy (MONO) or pembrolizumab plus platinum-based chemotherapy (COMB) should be selected for patients with advanced non-small-cell lung cancer (NSCLC) exhibiting high PD-L1 expression (tumor proportion scor
Publikováno v:
Case Reports in Oncology, Vol 14, Iss 3, Pp 1418-1421 (2021)
Case Reports in Oncology
Case Reports in Oncology
Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most serious adverse effects of chemotherapy. We experienced carboplatin (CBDCA)-induced akathisia-like CIPN, which was significantly attenuated by pregabalin administration, and report
Autor:
Hirofumi Takahashi, Jun Sakakibara‐Konishi, Megumi Furuta, Tetsuaki Shoji, Kosuke Tsuji, Daisuke Morinaga, Eiki Kikuchi, Junko Kikuchi, Takuro Noguchi, Kanako C. Hatanaka, Yutaka Hatanaka, Naofumi Shinagawa, Satoshi Konno
Publikováno v:
Cancer scienceREFERENCES.
Osimertinib is a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) that has shown marked antitumor activity in patients with EGFR-mutated non-small-cell lung cancer (NSCLC). However, these effects are transient
Autor:
Kosuke Tsuji, Makie Maeda, Eiki Kikuchi, Hirotoshi Dosaka-Akita, Hirofumi Takahashi, Satoshi Konno, Ichiro Kinoshita, Tetsuaki Shoji, Megumi Furuta, Jun Sakakibara-Konishi, Yuta Takashima, Junko Kikuchi
Publikováno v:
Cancer chemotherapy and pharmacology. 85:843-853
Purpose We evaluated the expression of proteasome subunits to assess whether the proteasome could be a therapeutic target in cisplatin-resistant lung cancer cells. Methods Cisplatin-resistant (CR) variants were established from three non-small cell l
Autor:
Hajime Kikuchi, Tetsuaki Shoji, Ichiro Kinoshita, Junko Kikuchi, Yuta Takashima, Megumi Furuta, Makie Maeda, Jun Sakakibara-Konishi, Satoshi Konno, Hirotoshi Dosaka-Akita, Motofumi Suzuki, Eiki Kikuchi
Publikováno v:
International journal of cancer. 146(4):1114-1124
Bromodomain and extraterminal domain (BET) inhibitors are broadly active against distinct types of cancer, including nonsmall cell lung cancer (NSCLC). Previous studies have addressed the effect of BET-inhibiting drugs on the expression of oncogenes